Blockchain Registration Transaction Record

BioStem Showcases Expanded Wound Care Portfolio at Premier SAWC Conference

BioStem Technologies showcases expanded perinatal tissue portfolio at SAWC Spring 2026, featuring Neox Product line and clinical evidence for advanced wound care solutions.

This news matters because it highlights significant advancements in regenerative medicine that directly impact patient care and clinical practice. BioStem's expanded portfolio, particularly the Neox Product line, represents important progress in wound healing technologies that could benefit millions suffering from chronic wounds like diabetic foot ulcers. The company's presentation of clinical trial data and practical guidance at SAWC means healthcare providers gain access to evidence-based solutions that could improve healing times and reduce complications. For patients, this translates to potentially better outcomes, reduced hospital stays, and improved quality of life. The regenerative medicine field is rapidly evolving, and BioStem's commitment to research and education helps advance the entire industry toward more effective treatments.